Nasal Drug Delivery

SNBL’s nasal drug delivery platform is a proprietary system consisting of powder carrier technology and delivery device technology.

Expertise in Nasal Delivery

3D Nasal Cast Model

preview
next
June 01, 2020
Satsuma Pharmaceuticals, Inc. (“Satsuma”, San Francisco, CA, USA) was established in June 2016 with the purpose of globally expanding the Translational Research business of Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”) by developing migraine therapeutics1) consisting of dihydroergotamine (“DHE”) and SNBL’s novel nasal delivery technology, STS101. Satsuma reported completion of enrollment and randomization in its EMERGE pivotal Phase 3 efficacy trial of STS101, a multi-center,...
May 19, 2020
Satsuma Pharmaceuticals, Inc. (“Satsuma”, San Francisco, CA, USA) was established in June 2016 with the purpose of globally expanding the Translational Research business of Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”) by developing migraine therapeutics consisting of dihydroergotamine (“DHE”) and SNBL’s novel nasal delivery technology, STS101. Two Satsuma posters were selected for presentation on the 2020 American Academy of Neurology Annual Meeting Science Highlights...
May 12, 2020
Satsuma Pharmaceuticals, Inc. (“Satsuma”, San Francisco, CA, USA) was established in June 2016 with the purpose of globally expanding the Translational Research business of Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”) by developing migraine therapeutics1) consisting of dihydroergotamine (“DHE”) and SNBL’s novel nasal delivery technology, STS101. Satsuma has reported its financial and business results for the first quarter of 2020. Satsuma anticipates no significant delays in...
February 03, 2020
Satsuma Pharmaceuticals, Inc. (“Satsuma”, San Francisco, CA, USA) was established in June 2016 with the purpose of globally expanding the Translational Research business of Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”) by developing migraine therapeutics1) consisting of dihydroergotamine (“DHE”) and SNBL’s novel nasal delivery technology, STS101. Satsuma announced that Phase 1 trial results detailing pharmacokinetics, tolerability, and safety with STS101 have been published...
September 17, 2019
Satsuma Pharmaceuticals, Inc. (“Satsuma”) located in California, USA, was established in 2016 licensing in nasal delivery technology originally developed by Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”). Satsuma was listed on the NASDAQ Stock Market on September 13, 2019. Satsuma is developing a nasal migraine drug, STS101 (dihydroergotamine). In the Phase I clinical study, STS101 achieved high absorption that was rapid and consistent using SNBL’s nasal delivery platform. Satsuma...
August 23, 2019
Satsuma Pharmaceuticals, Inc. (“Satsuma”, San Francisco, CA, USA) was established in June 2016 with the purpose to globally expand the Translational Research business of Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”) by developing migraine therapeutics1) consisting of dihydroergotamine (“DHE”) and SNBL’s novel nasal delivery technology, STS101. On August 22, 2019, Satsuma announced the completion of administration to the first patient in a Phase 3 EMERGE efficacy trial of...
April 25, 2019
Satsuma Pharmaceuticals, Inc. (“Satsuma”, San Francisco, CA, USA) was established in June 2016 with the purpose to globally expand the Translational Research business of Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”) by developing migraine therapeutics1) consisting of dihydroergotamine (“DHE”) and SNBL’s novel nasal delivery technology, STS101. On April 24, 2019, Satsuma announced a $62 million Series-B preferred stock financing led by Wellington Management Company with...
February 21, 2019
Satsuma Pharmaceuticals, Inc. (“Satsuma”, San Francisco, CA, USA) was established in June 2016 with the purpose to globally expand the Translational Research business of Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”) by developing migraine therapeutics1) using SNBL’s novel nasal delivery technology. Satsuma subsequently obtained funding from third party venture capital firms and conducted a Phase I clinical trial for its nasal dihydroergotamine formulation (“DHE”), STS101....
June 19, 2018
SNBL will be exhibiting a booth showcasing our proprietary nasal delivery technology, feasibility study program, and the application of Nose-to-Brain technology at the World Congress of Basic and Clinical Pharmacology in Kyoto (WCP2018) – July 02-05, 2018. Location: Kyoto International Conference Center Kyoto (ICC Kyoto, Takaragaike, Sakyo-ku, Kyoto 606-0001, Japan)
June 15, 2018
SNBL will present new data for our proprietary nasal delivery technology as applied to Nose-to-Brain and systemic delivery. The following posters will be presented at the Controlled Release Society (CRS) Annual Meeting in New York, NY – July 22-24, 2018: In Vitro/in Vivo Evaluations Of Nose-to-Brain Drug Delivery Platform Technology In Monkeys (Yusuke Torikai, poster number: 574) Pharmacokinetic Analysis of Absorption Characteristics of a Novel Nasal Zolmitriptan Powder Formulation in Monkeys...

Show more